Aug 28, 2023
DELIVER presentations at ESC Congress
May 23, 2023
DELIVER presentations at Heart Failure
May 9, 2023
Based on the positive results from the DELIVER Phase III trial, the FDA has extended approval of dapagliflozin to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure (HF) visits in adults with HF.
Dec 24, 2022
The American Heart Association recognizes DELIVER and the SGLT2 meta-analysis in the top cardiovascular research of 2022
Dec 15, 2022
DELIVER featured in Cardiology Today
Nov 4, 2022
DELIVER presentations at AHA
Nov 3, 2022
DELIVER presentations at ASN
Oct 4, 2022
DELIVER presentations at HFSA
